Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | CYB5R3 | P00387 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | TAS2R38 | P59533 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | LPO | P22079 | 2/20 | 0.51 |
| ▸ | MPO | P05164 | 1/20 | 0.51 |
| ▸ | TPO | P07202 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1287276 | 0.81 | SMN1; SMN2 (0.69) | SMN1; SMN2ALDH1A1DAOPARP1GPR84 | |
| SCHEMBL14123294 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2CYB5R3ALDH1A1CYP3A4TAS2R38 | |
| SCHEMBL9878921 | 0.80 | SMN1; SMN2 (0.67) | SMN1; SMN2CYB5R3ALDH1A1CYP3A4TAS2R38 | |
| Dimethylamine SCHEMBL27691701 | 0.77 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1DAOPARP1GPR84 | |
| SCHEMBL14917577 | 0.76 | SMN1; SMN2 (0.62) | SMN1; SMN2ALDH1A1CYP2C19DAOPARP1 | |
| SCHEMBL5907178 | 0.76 | SMN1; SMN2 (0.61) | SMN1; SMN2CYB5R3ALDH1A1CYP3A4TAS2R38 | |
| SCHEMBL14123256 | 0.76 | SMN1; SMN2 (0.60) | SMN1; SMN2CYB5R3ALDH1A1CYP3A4TAS2R38 | |
| SCHEMBL17206126 | 0.75 | GPR84 (0.73) | SMN1; SMN2GPR84 | |
| SCHEMBL30069796 | 0.74 | SMN1; SMN2 (0.59) | SMN1; SMN2CYB5R3ALDH1A1CYP3A4TAS2R38 | |
| SCHEMBL26440143 | 0.74 | SMN1; SMN2 (0.59) | SMN1; SMN2CYB5R3ALDH1A1CYP3A4TAS2R38 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240293441-A1 | NEW THERAPEUTIC USE OF TYPE 2 IODOTHYRONINE DEIODINASE (D2) INHIBITORS | CHEIRONTECH S.R.L. (IT) | 2024-09-05 | — | — | US | claimed |
| EP-4346841-A1 | NEW THERAPEUTIC USE OF TYPE 2 IODOTHYRONINE DEIODINASE (D2) INHIBITORS | Dompé Farmaceutici S.p.A. (IT) | 2024-04-10 | — | — | EP | claimed |
| CN-117320730-A | Novel therapeutic uses of inhibitors of type 2 iodinated thyronine deiodinase (D2) | 谢龙科技有限公司 | 2023-12-29 | — | — | CN | claimed |
| WO-2022253729-A1 | NEW THERAPEUTIC USE OF TYPE 2 IODOTHYRONINE DEIODINASE (D2) INHIBITORS | MATERIAS S.R.L. (IT) | 2022-12-08 | — | — | WO | claimed |
| US-20240293441-A1 | NEW THERAPEUTIC USE OF TYPE 2 IODOTHYRONINE DEIODINASE (D2) INHIBITORS | CHEIRONTECH S.R.L. (IT) | 2024-09-05 | — | — | US | disclosed |
| EP-4346841-A1 | NEW THERAPEUTIC USE OF TYPE 2 IODOTHYRONINE DEIODINASE (D2) INHIBITORS | Dompé Farmaceutici S.p.A. (IT) | 2024-04-10 | — | — | EP | disclosed |
| CN-117320730-A | Novel therapeutic uses of inhibitors of type 2 iodinated thyronine deiodinase (D2) | 谢龙科技有限公司 | 2023-12-29 | — | — | CN | disclosed |
| WO-2022253729-A1 | NEW THERAPEUTIC USE OF TYPE 2 IODOTHYRONINE DEIODINASE (D2) INHIBITORS | MATERIAS S.R.L. (IT) | 2022-12-08 | — | — | WO | disclosed |
| CN-108409635-B | Carbazole fluorescent thymine drug labeling reagent, synthesis and application | 曲阜师范大学 | 2021-06-18 | — | — | CN | disclosed |
| CN-110545850-A | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB | 2019-12-06 | — | — | CN | disclosed |
| WO-2016142486-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANTI-ANGIOGENIC RESISTANT CANCER | INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL) (ES) | 2016-09-15 | — | — | WO | disclosed |
| US-20140296399-A1 | PROCESS FOR PRODUCTION OF POLYLACTIC ACID RESIN COMPOSITION | KAO CORP (JP) | 2014-10-02 | — | — | US | disclosed |
| EP-1717267-A1 | Resin composition and molded product obtained therefrom | SONY CORPORATION (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-20060247340-A1 | RESIN COMPOSITION AND MOLDED PRODUCT OBTAINED THEREFROM | SONY CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
| EP-0287128-A1 | Antitumor agent | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1988-10-19 | — | — | EP | disclosed |
| US-4684728-A | Solubilizing biologically active compounds with reactive hydrogen atoms | BAYER AKTIENGESELLSCHAFT (DE) | 1987-08-04 | — | — | US | disclosed |
| EP-0017772-B1 | METHOD OF IMPROVING THE SOLUBILITY OF BIOLOGICALLY ACTIVE AGENTS IN WATER AND IN LOWER ALIPHATIC ALCOHOLS, AND COMPOUNDS HAVING AN IMPROVED SOLUBILITY | BAYER AG (DE) | 1982-07-28 | — | — | EP | disclosed |
| EP-0014263-B1 | METHOD OF IMPROVING THE SOLUBILITY OF BIOLOGICALLY ACTIVE AGENTS IN WATER AND IN LOWER ALIPHATIC ALCOHOLS, AND COMPOUNDS HAVING AN IMPROVED SOLUBILITY | BAYER AG (DE) | 1982-05-05 | — | — | EP | disclosed |
| EP-0017772-A1 | Method of improving the solubility of biologically active agents in water and in lower aliphatic alcohols, and compounds having an improved solubility | BAYER AG (DE) | 1980-10-29 | — | — | EP | disclosed |
| EP-0014263-A2 | Method of improving the solubility of biologically active agents in water and in lower aliphatic alcohols, and compounds having an improved solubility | BAYER AG (DE) | 1980-08-20 | — | — | EP | disclosed |